

10014485.031202

Express Mail Label No.: EF176736570US

Date of Deposit: March 18, 2002

Attorney Docket No. CST-138 CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICANTS: Comb *et al.*
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.
SERIAL NUMBER: 10/014,485 EXAMINER: Not yet assigned
FILING DATE: November 13, 2001 ART UNIT: 1627
FOR: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES
USING PEPTIDE LIBRARIES AS ANTIGENS

March 18, 2002
Beverly, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Attached hereto for filing in the above-identified patent application is/are:

- ☒ Response to Notice to File Corrected Application Papers (2 pages);
- ☒ Copy of Notice (2 pages);
- ☒ Substitute Formal Drawings (25 sheets, Figures 1A-29);
- ☒ Copy of Submission of Computer-Readable Copy of Sequence Listing (2 pages);
- ☒ Transmittal Letter (w/duplicate) (2 pages);
- ☒ Return Postcard.

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.
166B Cummings Center
Beverly, Massachusetts 01915
Tel: (978) 867-2311
Fax: (978) 867-2400

Express Mail Label No.: EF176736570US

Date of Deposit: March 18, 2002

Attorney Docket No. CST-138 CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Comb *et al.*
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.
SERIAL NUMBER: 10/014,485 EXAMINER: Not yet assigned
FILING DATE: November 13, 2001 ART UNIT: 1627
FOR: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES
USING PEPTIDE LIBRARIES AS ANTIGENS

March 18, 2002
Beverly, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

**RESPONSE TO NOTICE TO FILE CORRECTED
APPLICATION PAPERS**

The present papers are being filed in response to the Notice to File Corrected Application Papers, dated January 16, 2002, received in the above-identified patent application. These documents are due March 18, 2002.

In response to the requirement to file substitute drawings in compliance with 37 C.F.R. §1.84, Applicants submit herewith 25 sheets of formal substitute drawings (Figures 1A-29) that: (i) conform to the margin requirements, (ii) have shortened legends, and (iii) are on paper that is flexible, strong, white, smooth, non-shiny, and durable. These substitute drawings do not introduce new matter. Applicants submit that these substitute drawings are of publication quality and conform to the requirements of 37 C.F.R. §1.84.


In response to the requirement to file a substitute computer-readable copy of the Sequence Listing in compliance with 37 C.F.R. §1.823, Applicants are concurrently filing (with the Sequence Division) a substitute computer-readable copy correcting the errors noted in the provided marked-up raw sequence listing. A copy of the concurrently filed paper is enclosed herewith for the Examiner's convenience.

Lastly, the Commissioner is hereby authorized to charge the \$140.00 fee for the outstanding multiple-dependent claim surcharge to Deposit Account No. 50-1774, Ref. No. CST-138 CIP2.

APPLICANTS: Comb *et al.*
U.S.S.N.: 10/014,485

Applicants believe that no additional fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to the above-referenced Deposit Account.

Respectfully submitted,



James Gregory Cullem, Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.
166B Cummings Center
Beverly, MA 01915
(978) 867-2311

Dated: March 18, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 10/014,485 | 11/13/2001 | Michael J. Comb | CST-138 CIP2 |

CELL SIGNALING TECHNOLOGY, INC.
Intellectual Property Counsel
166B Cummings Center
Beverly, MA 01915



CONFIRMATION NO. 4101

FORMALITIES LETTER



OC00000007316952

Date Mailed: 01/16/2002

The required items noted below SHOULD be filed along with any items required above. The filing date of this nonprovisional application will be the date of receipt of the items required above.

- Total additional claim fee(s) for this application is \$140.
 - \$140 for multiple dependent claim surcharge.
- The balance due by applicant is \$ 140.

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1 0 cm. (3/8 inch);
 - drawings contain excessive text. Suitable descriptive legends may be used, or may be required by the Examiner where necessary for understanding of the drawing but should contain as few words as possible (see 37 CFR 1.84(o));
 - drawings submitted to the Office are not electronically reproducible. Drawing sheets must be submitted on paper which is flexible, strong, white, smooth, non-shiny, and durable (see 37 CFR 1.84(e));

- An Abstract not to exceed 150 words in length, commencing on a separate sheet (37 CFR 1.72(b)).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Express Mail Label No.: EF176736637US

Date of Deposit: March 18, 2002

10/014,485, 03/18/02

Attorney Docket No. CST-138 CIP2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Comb *et al.*
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.
SERIAL NUMBER: 10/014,485 EXAMINER: Not yet assigned
FILING DATE: November ART UNIT: 1627
FOR: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES
USING PEPTIDE LIBRARIES AS ANTIGENS

March 18, 2002
Beverly, Massachusetts

U.S. Patent & Trademark Office
Box SEQUENCE, P.O. Box 2327
Arlington, VA 22202

**SUBMISSION OF PAPER COPY AND/OR COMPUTER-READABLE
COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

1. ☒ This paper is in response to the Patent Office letter dated January 16, 2002.

☒ A copy of the Patent Office letter is enclosed.

Note If these papers are filed before the Patent Office letter is mailed, the adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of the invention, the filing date on the Express Mail Label, the USSN from the return postcard or the attorney's docket number must be added

☒ This paper is in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.

☐ This paper is being filed simultaneously with a request for filing of a new patent application.

2. Submitted herewith are:

☐ A Preliminary Amendment directing entry of the Sequence Listing into the specification;

☐ a paper copy of the Sequence Listing for the above-identified patent application with each sequence assigned a separate identifier; and

☒ a substitute copy of the Sequence Listing in computer-readable form for the above-identified patent application.

APPLICANTS: Comb *et al.*
U.S.S.N.: 10/014,485

10014485-1051902

3. Statement:

I hereby state that: *(complete applicable items -- A, B and/or C)*

- A. ☐ The content of the paper and computer-readable copies of the Sequence Listing submitted herewith are the same.
- B. ☒ The content of the computer-readable copy of the Sequence Listing submitted herewith is the same as the Sequence Listing appearing at the end of the originally-filed specification.
- C. ☒ This submission includes no new matter.

The substitute computer-readable copy of the Sequence Listing submitted herewith corrects the format errors in the originally-filed computer-readable copy. Specifically, the <223> responses for SEQ ID NOs: 88, 96, 101, 105, 109, and 111 have been revised to comply with the 4 line limit of 37 C.F.R. §1.823(b). For the Sequence examiner's convenience, paper copies of these revised responses are enclosed herewith.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-1774, Ref. No. CST-138 CIP2.

Respectfully submitted,



James Gregory Cullem, Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.
166B Cummings Center
Beverly, MA 01915
(978) 867-2311

Dated: March 18, 2002